WAVY-TV

GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended ...

MENLO PARK, Calif., Oct. 17, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive ...
Nasdaq

GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study

MENLO PARK, Calif., June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line ...
Insider Monkey

GRAIL’s Galleri Multi-Cancer Test Shows Strong Performance in PATHFINDER 2 Study, Paves Way for FDA Submission

GRAIL Inc. (NASDAQ:GRAL) is one of the best young stocks to buy and hold for 5 years. On June 18, GRAIL announced positive top-line performance and safety results from the pre-specified analysis of ...
Seeking Alpha

GRAIL, Inc. (GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection Transcript

Good day, ladies and gentlemen, and welcome to today's GRAIL analyst call. [Operator Instructions] Please be advised that this conference call is being recorded. GRAIL Investor Relations. Please begin ...
Business Wire

Final Results From PATHFINDER Study of GRAIL’s Multi-Cancer Early Detection Blood Test Published in The Lancet

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings from the PATHFINDER study of ...